English 
FRONTEOと丸石製薬、創薬AIファクトリーを活用したバイオマーカー探索の共創プロジェクトを開始
既知の文献情報から疾患と分子の未知の関連性を体系的に発見する独自技術により、医療用医薬品の研究開発を加速
株式会社FRONTEOと丸石製薬株式会社は、ライフサイエンスAI（AI創薬）分野におけるバイオマーカー（※1）探索の共創プロジェクトを開始することをお知らせいたします。
In clinical trials for drug development, the use of biomarkers, which play an important role in determining the mechanism of action and therapeutic effects of drugs, has been shown to provide excellent safety and good efficacy outcomes (1). In this co-creation project, we will combine FRONTEO’s AI drug discovery support service “FRONTEO Drug Discovery AI Factory” (DDAIF) (*2), which specializes in hypothesis generation, with Maruishi Pharmaceutical’s accumulated knowledge and technology in drug research and development to find appropriate biomarkers, thereby accelerating Maruishi Pharmaceutical’s drug research and development.
Maruishi Pharmaceutical’s main targets are the fields of perioperative, acute and emergency medical care, infection control, and supportive medical care (cancer supportive care), and in order to meet unmet medical needs (*3) including surrounding areas, the company is engaged in integrated research and development activities, including the search for R&D seeds, basic drug discovery research, formulation design, CMC (*4) related tests, non-clinical trials, clinical trials, and even post-marketing drug development.
FRONTEO will utilize its proprietary, specialized AI “KIBIT” natural language processing technology (patented) in co-creation projects with multiple pharmaceutical companies to improve the success rate of drug development for client companies and contribute to people’s health.
ソース 日本経済新聞
日本語